Skip to content
Biodatica
Start free

Novartis Pharmaceuticals

Birmingham, Alabama

OncologyFiled/ApprovedListed · NVS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

4d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Aug 27, 2025

    HR+/HER2- Early Breast Cancer · RECRUITING · sponsor: Novartis Pharmaceuticals · RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

    ClinicalTrials.gov · NCT06797531 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 21, 2025

    Glomerulonephritis, IGA, Immunoglobulin A Nephropathy · RECRUITING · sponsor: Novartis Pharmaceuticals · Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

    ClinicalTrials.gov · NCT06797518 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Feb 28, 2024

    Early Breast Cancer · RECRUITING · sponsor: Novartis Pharmaceuticals · Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    ClinicalTrials.gov · NCT05827081 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Dec 7, 2023

    Chronic Inducible Urticaria · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

    ClinicalTrials.gov · NCT05976243 (opens the source filing in a new tab)

  5. Trial

    PHASE4 registered

    Aug 9, 2022

    Advanced Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

    ClinicalTrials.gov · NCT05631795 (opens the source filing in a new tab)

  6. Trial

    PHASE4 registered

    Jun 10, 2021

    Sickle Cell Disease · RECRUITING · sponsor: Novartis Pharmaceuticals · Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

    ClinicalTrials.gov · NCT04657822 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources